dc.contributor
Institut Català de la Salut
dc.contributor
[Solomon BJ] Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. [Bauer TM] Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA. [Mok TSK] State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong, Special Administrative Region of China, China. [Liu G] University Health Network, Toronto, ON, Canada. [Mazieres J] Toulouse University Hospital, Toulouse, France. [Marinis F] European Institute of Oncology, IRCCS, Milan, Italy. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Solomon, Benjamin
dc.contributor.author
Bauer, Todd
dc.contributor.author
Mok, Tony
dc.contributor.author
MAZIERES, JULIEN
dc.contributor.author
de Marinis, Filippo
dc.contributor.author
Liu, Geoffrey
dc.contributor.author
FELIP, ENRIQUETA
dc.date.issued
2023-07-03T11:43:34Z
dc.date.issued
2023-07-03T11:43:34Z
dc.identifier
Solomon BJ, Bauer TM, Mok TS, Liu G, Mazieres J, De Marinis F, et al. Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer. Futur Oncol. 2023 May;19(14):961–73.
dc.identifier
https://hdl.handle.net/11351/9947
dc.identifier
10.2217/fon-2022-1289
dc.description.abstract
Lorlatinib; Non-small-cell lung cancer
dc.description.abstract
Lorlatinib; Cáncer de pulmón de células no pequeñas
dc.description.abstract
Lorlatinib; Càncer de pulmó de cèl·lules no petites
dc.description.abstract
What is this summary about?
This summary shows the updated results of an ongoing research study called CROWN that was published in The Lancet Respiratory Medicine in December 2022. In the CROWN study, researchers looked at the effects of two study medicines called lorlatinib and crizotinib. The study included people with advanced non-small-cell lung cancer (NSCLC) that had not been treated previously. All people in the study had cancer cells with changes (known as alterations) in a gene called anaplastic lymphoma kinase, or ALK. This ALK gene is involved in cancer growth. In this updated study, researchers looked at the continued benefit in people who took lorlatinib compared with people who took crizotinib after 3 years.
What did this study find?
After 3 years of being observed, people who took lorlatinib were more likely to be alive without their cancer getting worse than people who took crizotinib. At 3 years, 64% of people who took lorlatinib were alive without their cancer getting worse compared with 19% of people who took crizotinib. The cancer was less likely to have spread within or to the brain in people who took lorlatinib than in people who took crizotinib. After 3 years of being observed, 61% of people were still taking lorlatinib and 8% of people were still taking crizotinib. People who took lorlatinib had more severe side effects than people who took crizotinib. However, these side effects were manageable. The most common side effects with lorlatinib were high levels of cholesterol or high levels of triglycerides (a type of fat) in the blood. Life-threatening side effects were seen in 13% of people who took lorlatinib and 8% in crizotinib. Two people who took lorlatinib died because of side effects from lorlatinib.
What do the results of the study mean?
The updated results from the CROWN study showed that a larger percentage of people who took lorlatinib continued to benefit from their treatment after being observed for 3 years compared with those who took crizotinib.
dc.description.abstract
This study was sponsored by Pfizer Inc.
dc.format
application/pdf
dc.publisher
Future Medicine
dc.relation
Future Oncology;19(14)
dc.relation
https://doi.org/10.2217/fon-2022-1289
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Pulmons - Càncer - Tractament
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.title
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
